MetaCap

Bicycle Therapeutics (BCYC) vs NervGen Pharma (NGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NervGen Pharma (NGEN) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 35.0% versus a loss of 54.1%. Over five years, NGEN leads with a -9.6% price change compared with -94.7% for BCYC. Bicycle Therapeutics is the larger company by market cap ($203.3 million vs $198.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCYC-54.11%NGEN-35.04%
+118%+28%-62%
Nov 21, 20251 yearNov 20, 2026
BCYC-95.01%NGEN-16.85%
+178%+35%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCYC versus NGEN key metrics
MetricBCYCNGEN
Share price$2.90$1.85
Market cap$203.27M$198.55M
1-day change-4.92%-3.91%
YTD return-59.04%-67.05%
1-year return-54.11%-35.04%
5-year return-94.69%-9.56%
EPS (TTM)$-2.03$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.59M—
Revenue growth (YoY)+105.77%—
Net income (latest FY)$-218.96M—
Operating margin-340.38%—
Net margin-301.66%—
52-week high$7.83$6.30
52-week low$2.85$1.28
Distance from 52-week high-62.96%-70.71%
Analyst consensusbuystrong_buy
Avg. price target upside+216.21%+442.01%
Average volume444.72K621.66K
Shares outstanding50.66M107.62M
Employees2889
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NGEN has outperformed BCYC by 19.1 percentage points over the past year.

About Bicycle Therapeutics

BCYC stock →

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.

Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees

About NervGen Pharma

NGEN stock →

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

BCYC vs NGEN FAQ

Which is bigger, Bicycle Therapeutics or NervGen Pharma?

Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $203.27M compared with $198.55M for NervGen Pharma (NGEN).

Which stock has performed better over the past year, BCYC or NGEN?

NGEN returned -35.04% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.

Are Bicycle Therapeutics and NervGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons